GU Cancers 2019 | Defining platinum ineligibility in mUC

Cisplatin-based chemotherapy has been established as an important first-line treatment for metastatic urothelial carcinoma (mUC). However, a subset of patients are ineligible to receive cisplatin and have limited treatments options. Shilpa Gupta, MD, of the University of Minnesota, Minneapolis, MN, highlights the need for a clear definition for “platinum-ineligibility” in mUC patients for deciding on optimal treatments. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Gupta lists the parameters that could assist in defining “platinum-ineligible” mUC.